Abstracts tagged "Infection"

Abstract Number: 0100 • ACR Convergence 2020
Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Cristobal Pavez Perales¹, Ana Quiles Rocher², Elena Grau Garcia³, Marta De la Rubia Navarro¹, Samuel Leal Rodriguez⁴, Roxana Gonzalez Mazario¹, Jorge Juan Fragio Gil¹, Cristina Alcañiz Escandell³, Jose Ivorra Cortes¹, Inmaculada Chalmeta Verdejo¹, Luis Gonzalez Puig⁵, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁴, Elvira Vicens Bernabeu⁴, Carmen Najera Herranz¹, Ines Canovas Olmos¹ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Medical School, UCV, Valencia, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain
Background/Purpose: Patients with rheumatic diseases (RD) are at higher risk of latent tuberculosis infection (LTBI) reactivation. To detect and treat it before starting treatment, especially with biological therapies, decrease the reactivation risk. Diagnosis is carried…
Abstract Number: 0631 • ACR Convergence 2020
Clinical Manifestations and Outcomes in DMARD-Naïve Patients with Chronic Chikungunya Arthritis
Nicolle Medina-Cintrón¹, Idali Martínez¹, Naydi Pérez-Ríos², Yaritza Berríos-López² and Luis Vilá³, ¹University of Puerto Rico Medical Science Campus, San Juan, Puerto Rico, ²University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ³University of Puerto Rico Medical Sciences Campus, San Juan
Background/Purpose: Chikungunya virus (CHIKV) is characterized by fever, maculopapular rash, and severe polyarthralgia and polyarthritis. Up to 80% of affected individuals may develop chronic CHIKV…
Abstract Number: 1469 • ACR Convergence 2020
Characteristics of Adult Patients with Rheumatic Diseases During the COVID-19 Pandemic: Data from an International Patient Survey
Jonathan Hausmann¹, Kevin Kennedy², Salman Surangiwala³, Maggie Larche⁴, Mitchell Levine², Jean Liew⁵, Zachary Wallace⁶ and Emily Sirotich⁴, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Washington, Seattle, WA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with rheumatic diseases are at increased risk of infection due to immune dysregulation and the use of immunosuppression. It is unknown whether they…
Abstract Number: 0223 • ACR Convergence 2020
Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB)
Anna Davidson¹, Alize Gunay¹, Ines Colmegna², Diane Lacaille³, Harold Loewen⁴, Michele Meltzer⁵, Yewondwossen Tadese⁶, Zenebe Yirsaw⁶, Sasha Bernatsky⁷ and Carol Hitchon⁴, ¹McGill University, Montreal, QC, Canada, ²The Research Institute of the McGill University Health Centre, Montreal, Canada, ³University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Jefferson University, Philadelphia, PA, ⁶Addis Ababa University, Addis Ababa, Adis Abeba, Ethiopia, ⁷The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Increased awareness of the importance of MTX in rheumatic disease is leading to more MTX use in patients from TB-endemic areas. Current management guidelines…
Abstract Number: 0632 • ACR Convergence 2020
Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases
Valeria Valerio¹, Mariana Useche¹, Erin Field², Mianbo Wang³, Elizabeth M. Hazel⁴, Brian Ward⁵ and Ines Colmegna¹, ¹The Research Institute of the McGill University Health Centre, Montreal, Canada, ²The Research Institute of the MUHC, Montreal, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, Canada, ⁵The Research Institute of the McGill University Health Centre, Monreal, QC, Canada
Background/Purpose: A vaccination coverage goal of 80% with the seasonal influenza vaccine was established to protect people at high-risk for influenza-related complications or hospitalizations (e.g.…
Abstract Number: 1478 • ACR Convergence 2020
A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center
Juan C Sarmiento-Monroy¹, Gerard Espinosa², Fernanda Meira¹, Berta Caballol³, Maria C Londoño³, Sara Llufriu³, Aina Moll¹, Luis Fernando Quintana Porras¹, Felipe Julio Ramirez Garcia⁴, José Inciarte-Mundo¹, Elisabeth Solana¹, Yolanda Blanco¹, Eugenia Martinez¹, Victor Llorens¹, Sergio Prieto-González⁵, Georgina Espigol¹, Jose C Milisenda¹, Maria C. Cid⁵, Priscila Giavedoni¹, Jose M Mascaró¹, Isabel Blanco¹, Joan Albert Barbera¹, Oriol Sibila¹, Jordi Gratacos-Gines¹, Alfredo Adan², Alvaro Agustí¹, Raimon Sanmartí⁶, Julián Panés¹, Ricard Cervera¹, Jordi Vila¹, Alex Soriano¹, Jose Gómez-Puerta⁶ and On behalf INMUNOCOVID CLINIC⁷, ¹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²Hospital Clinic, Barcelona, Catalonia, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁵Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Hospital Clinic de Barcelona, Barcelona
Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…
Abstract Number: 0227 • ACR Convergence 2020
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Lucía Vega-Álvarez¹, Itziar Calvo-Zorrilla¹, Oihane Ibarguengoitia-Barrena¹, Juan M. Blanco-Madrigal¹, David Montero-Seisdedos², Carmen L. Garcia-Gomez¹, Maria Esther Ruiz-Lucea¹, Ana R. Inchaurbe-Pellejero¹, Ignacio Torre-Salaberri¹, Clara E. Perez-Velasquez¹, Olaia Fernandez-Berrizbeitia¹, Eduardo Cuende-Quintana³, Iñigo R. Gorostiza-Hormaetxe⁴, María Luz García-Vivar¹ and Eva Galindez-Agirregoikoa¹, ¹Basurto University Hospital, BILBAO, Spain, ²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ³Basurto University Hospital, Madrid, Spain, ⁴Basurto University Hospital, Bilbao
Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
Abstract Number: 0633 • ACR Convergence 2020
Vitamin D Serum Status in a Cohort of COVID-19 Patients
Alberto Sulli¹, Emanuele Gotelli¹, Sabrina Paolino¹, Andrea Casabella¹, Carmen Pizzorni¹, Elisa Alessandri¹, Vanessa Smith² and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium
Background/Purpose: Vitamin D serum levels have been inversely associated with risk of pulmonary infections and autoimmune inflammatory disease activity and severity [1,2]. A possible role…
Abstract Number: 1568 • ACR Convergence 2020
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
Nilasha Ghosh¹, Aidan Tirpack², Caroline Benson³, Gregory Vitone³, Karmela Kim Chan² and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
Abstract Number: 0264 • ACR Convergence 2020
Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus
Nouf Alhammadi¹, Murray Urowitz² and Dafna Gladman³, ¹University of Toronto, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Leukopenia in SLE is defined as leukocyte count below 4,000/mm3 on two or more occasions according to the ACR criteria and may include a…
Abstract Number: 0635 • ACR Convergence 2020
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
Bonnia Liu¹, Victor Yang², Christopher McMaster³, Russell Buchanan⁴, Albert Frauman⁵ and David Liew⁶, ¹Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, ²Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ⁶Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
Abstract Number: 1620 • ACR Convergence 2020
Hepatitis B Screening Practices When Prescribing Tocilizumab or Tofacitinib in Real World Practice
Naomi Serling-Boyd¹, Amir Mohareb², Arthur Kim², Emily Hyle² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Hepatitis B virus (HBV) reactivation can complicate treatment with immunosuppressive medications. Reactivation risk varies by the status of HBV infection but has been reported…
Abstract Number: 0430 • ACR Convergence 2020
Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network
Kristin D'Silva¹, April Jorge¹, Na Lu², Yuqing Zhang³, Zachary Wallace⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.Methods: We conducted…
Abstract Number: 0637 • ACR Convergence 2020
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
Benjamin Naovarat¹, Francis Williams¹ and John Reveille², ¹The University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
Abstract Number: 1623 • ACR Convergence 2020
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Bonnie Bermas², Puneet Bajaj³, Nagendra Pokala¹, Reuben Arasaratnam⁴, Joan Reisch¹ and Dan (Clarie) Wang¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UTSouthwestern.edu, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are particularly vulnerable to pneumococcal infection due to both their underlying disease and immunosuppressive therapy. Thus, quality improvement metrics include increasing pneumococcal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].